Medical Condition News

RSS

Alzheimer's Association appreciates RCN for its generous donation and awareness campaign

RCN Corporation recently donated more than $10,000 towards the Alzheimer's Association, National Capital Area Chapter's Reflections campaign and the nonprofit's signature event, the National Memory Walk. Earlier in the year, the company committed $210,000 in donated cable time for cross-channel spots about local Alzheimer initiatives in 2009.

23 Oct 2009

Physicians' negative attitudes toward obese patients can affect quality of care

Doctors have less respect for their obese patients than they do for patients of normal weight, a new study by Johns Hopkins researchers suggests. The findings raise questions about whether negative physician attitudes about obesity could be affecting the long-term health of their heavier patients.

23 Oct 2009

New guidelines from American Academy of Dermatology for treatment of psoriasis with ultraviolet light therapy

Based on an extensive review of the highest quality scientific literature on psoriasis and the opinion of recognized psoriasis experts, the American Academy of Dermatology (Academy) has released new guidelines of care for the management and treatment of psoriasis with ultraviolet (UV) light therapy, also known as phototherapy. Recommendations for the use of the most common forms of UV light therapy, as stand-alone treatments or in conjunction with other therapies, were outlined, including patient considerations.

23 Oct 2009

Play less video games to keep your focus

Parents have long lectured their children about the mind-numbing effects of playing video games all day. And a new Iowa State University study has found that high volume action video game players -- those who play around 40 hours per week -- actually had more difficulty keeping focused on tasks requiring longer, more proactive attention than those who played video games less than a couple of hours a week.

23 Oct 2009

Canadian Cardiovascular Society to honor University of Alberta medical researcher

A University of Alberta medical researcher being hailed as a world leader in his field will receive a major national award for his pioneering work in the development of a new class of drugs for the treatment of heart failure.

23 Oct 2009

Liraglutide drug causes less nausea and hypoglycaemia compared to exenatide

New data on patient treatment satisfaction from the LEAD(TM) 6 trial presented on the 22nd October at the 20th World Diabetes Congress (International Diabetes Federation) shows that patients have higher overall treatment satisfaction with liraglutide than they do with exenatide.

23 Oct 2009

Intellectual property covering compounds that have utility in treating SMA licensed

Repligen Corporation announced today that it has entered into an exclusive license agreement with Families of Spinal Muscular Atrophy (FSMA) for intellectual property covering compounds which may have utility in treating Spinal Muscular Atrophy (SMA).

23 Oct 2009

Non-adherence to medication may be the cause for difficult asthma

Difficult-to-treat asthma often may have more to do with patients who do not take their medication as instructed than ineffective medication, according to researchers in Northern Ireland.

23 Oct 2009

Aethlon Medical establishes ESI as a wholly owned subsidiary

Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) announced today that it has established Exosome Sciences, Inc. (ESI) as a wholly owned subsidiary of the Company.

23 Oct 2009

American Thoracic Society releases new clinical guidelines for pulmonary exacerbation of cystic fibrosis

The American Thoracic Society has released new clinical guidelines for the treatment of exacerbations in cystic fibrosis based on a review of the literature on current clinical practices.

23 Oct 2009

AJC urges Egyptian government to allow Israeli breast cancer researchers to enter the country

The American Jewish Committee urged the Egyptian government to allow a team of Israeli breast cancer researchers to enter the country for a major conference sponsored by Susan G. Komen for the Cure, a leading breast cancer awareness group based in the U.S. The Israeli team was denied entry into Egypt earlier this week, despite having previously received the necessary clearances to attend the conference in Alexandria.

23 Oct 2009

TargeGen completes JAK2 inhibitor TG101348 clinical trial in myelofibrosis patients

TargeGen, Inc. today announced that the Company has successfully completed a 59 patient, multicenter clinical trial of TG101348, an oral, potent, and highly selective inhibitor of JAK2 in patients with myelofibrosis.

23 Oct 2009

AAFP receives MetLife Foundation grant to counter childhood obesity

The American Academy of Family Physicians (AAFP) and the AAFP Foundation announce that they have been awarded a $150,000 grant from MetLife Foundation, designed to counter the national epidemic of childhood obesity by empowering family physicians with new ways to promote physical activity, nutrition and emotional well-being. The partnership will produce educational materials for children, including books and publications.

23 Oct 2009

Majority of allergy patients can be vaccinated against swine flu after evaluation by an allergist

Once supply catches up with the immediate demand for H1N1 "swine" flu vaccine, some allergy patients who could benefit from the vaccine may needlessly avoid it due to confusion over who should, and should not, be vaccinated, cautions Dr. Peter R. Smith, a board-certified allergist and clinical immunologist with Allergy Partners of Fredericksburg, Virginia.

23 Oct 2009

Important guidelines from IDF for diabetes care

The Guidelines are the work of the IDF Task Force on Clinical Guidelines, which is focused on meeting the critical global need to provide up-to-date evidence-based information and training for healthcare professionals.

23 Oct 2009

FDA grants IDE approval to Harvest Technologies to commence its BMAC Enhanced CABG trial

Harvest Technologies Corp. (www.harvesttech.com) announced today that the Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to commence its BMAC Enhanced CABG Trial. This is a two phase 42-patient 'feasibility' clinical trial using the company's BMAC System to concentrate autologous bone marrow cells to treat patients with congestive heart failure undergoing treatment with coronary artery bypass grafting (CABG) Surgery.

22 Oct 2009

NCI awards $2.8 million grant to Allegro Diagnostics

Allegro Diagnostics, a leader in the field of molecular diagnostics for lung cancer, has announced that its clinical study for BronchoGen(TM), a diagnostic test for patients suspected of having lung cancer, will receive up to $2.8 million in funding for a Phase I/II Fast Track Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI).

22 Oct 2009

LIVALO statin effective than simvastatin in reducing lipid levels

New Phase III data published today in "Current Medical Research and Opinion" highlight that the recommended starting dose of 2 mg of LIVALO (pitavastatin), a novel synthetic statin, was statistically superior to simvastatin at a dose of 20 mg over 12 weeks in reducing low-density lipoprotein cholesterol

22 Oct 2009

KemPharm commences KP106 Phase 1 clinical trial for ADHD

KemPharm, Inc. today announced that it has commenced a Phase 1 clinical trial in healthy volunteers of its novel prodrug compound, KP106, which is in development for the treatment of attention-deficit hyperactivity disorder (ADHD). KP106, a new chemical entity (NCE) composed of d-amphetamine and a ligand, is the lead investigational candidate from KemPharm’s proprietary ligand activated therapy (LAT) platform, which creates improved versions of FDA-approved drugs. KemPharm began the KP106 program in 2007 and has initiated the Phase 1 clinical trial of this candidate in less than 24 months.

22 Oct 2009

Positive results from Aerie Pharmaceuticals’ Phase 2a study of its Rho-kinase inhibitor

Aerie Pharmaceuticals, a biotechnology company focused on the discovery and development of novel treatments for glaucoma, today announced positive results from a Phase 2a study of its Rho-kinase (ROCK) inhibitor, AR-12286. The study evaluated the safety, tolerability and efficacy of three different doses of AR-12286 in 88 patients with primary open angle glaucoma or ocular hypertension.

22 Oct 2009

Medical Condition News

Alzheimer's Association appreciates RCN for its generous donation and awareness campaign

Physicians' negative attitudes toward obese patients can affect quality of care

New guidelines from American Academy of Dermatology for treatment of psoriasis with ultraviolet light therapy

Play less video games to keep your focus

Canadian Cardiovascular Society to honor University of Alberta medical researcher

Liraglutide drug causes less nausea and hypoglycaemia compared to exenatide

Intellectual property covering compounds that have utility in treating SMA licensed

Non-adherence to medication may be the cause for difficult asthma

Aethlon Medical establishes ESI as a wholly owned subsidiary

American Thoracic Society releases new clinical guidelines for pulmonary exacerbation of cystic fibrosis

AJC urges Egyptian government to allow Israeli breast cancer researchers to enter the country

TargeGen completes JAK2 inhibitor TG101348 clinical trial in myelofibrosis patients

AAFP receives MetLife Foundation grant to counter childhood obesity

Majority of allergy patients can be vaccinated against swine flu after evaluation by an allergist

Important guidelines from IDF for diabetes care

FDA grants IDE approval to Harvest Technologies to commence its BMAC Enhanced CABG trial

NCI awards $2.8 million grant to Allegro Diagnostics

LIVALO statin effective than simvastatin in reducing lipid levels

KemPharm commences KP106 Phase 1 clinical trial for ADHD

Positive results from Aerie Pharmaceuticals’ Phase 2a study of its Rho-kinase inhibitor

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Latest News